← Back to Search

SGLT-2 Inhibitor

Active for Myocarditis

Phase 4

Waitlist Available

Led By Xue-Qiao Zhao, MD

Research Sponsored by University of Washington

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up approximately 12 months

Awards & highlights

Study Summary

This trial will investigate the effects of SGLT-2 inhibition on myocardial strain, fibrosis, and inflammation as assessed by cardiac MRI with T1- and T2-mapping in patients with type-2 diabetes.

Eligible Conditions

Myocardial Fibrosis
Myocarditis
Type 2 Diabetes

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ approximately 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~approximately 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Extracellular Volume Fraction (ECV)

Global Myocardial Strain

Secondary outcome measures

T2 Relaxation Time

Other outcome measures

Fasting Glucose

HbA1C

hsCRP

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: ActiveActive Control1 Intervention

10mg tabs of dapagliflozin

Group II: PlaceboPlacebo Group1 Intervention

10mg tabs placebo matching dapagliflozin.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of WashingtonLead Sponsor

1,738 Previous Clinical Trials

1,844,289 Total Patients Enrolled

AstraZenecaIndustry Sponsor

4,257 Previous Clinical Trials

288,593,724 Total Patients Enrolled

Xue-Qiao Zhao, MDPrincipal InvestigatorUniversity of Washington

3 Previous Clinical Trials

523 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What level of risk is associated with using Active?

"Given this is a Phase 4 trial, which indicates approval from regulatory bodies, the safety of Active was rated highly at 3 on our team's scale."

Answered by AI

To what end is Active most frequently employed?

"Active is a widely used pharmaceutical preparation for treating various health conditions, including diet and exercise. It may also provide benefits when employed as monotherapy for individuals whose responses to medication have been unsatisfactory."

Answered by AI

Is this research a pioneering endeavor?

"Active has been under examination since 2014, when AstraZeneca sponsored the first trial which included 700 patients. After its initial assessment, it was granted N/A designation and is now being tested in 63 separate trials at 235 locations across 50 nations."

Answered by AI

What is the total sample size of this research study?

"Unfortunately, this trial is no longer seeking participants; its listing was last updated on July 25th 2022. However, there are 1616 and 63 clinical trials respectively that currently have open recruitment for patients with type 2 diabetes mellitus and Active conditions."

Answered by AI

Are participants still being sought for this experiment?

"The recruitment period for this clinical trial has ended. Initially posted on February 26th 2019 and last updated on July 25th 2022, it is no longer accepting participants. Fortunately, 1616 different studies are currently enrolling patients with type 2 diabetes mellitus while 63 trials are actively searching for individuals suffering from the condition."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2

Francis Kim 2019. "Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03782259.